title: Human albumin solution for resuscitation and volume expansion in critically ill patients.
abstract: BACKGROUND
  Human albumin solutions are used in a range of medical and surgical problems. Licensed indications are the emergency treatment of shock and other conditions where restoration of blood volume is urgent, burns, and hypoproteinaemia. Human albumin solutions are more expensive than other colloids and crystalloids.
  
  
  OBJECTIVE
  To quantify the effect on mortality of human albumin and plasma protein fraction (PPF) administration in the management of critically ill patients.
  
  
  METHODS
  We searched the Cochrane Injuries Group trials register, Cochrane Central Register of Controlled Trials, Medline, Embase and BIDS Index to Scientific and Technical
  Reference lists of trials and review articles were checked, and authors of identified trials were contacted. The search was last updated in August 2004.
  
  
  METHODS
  Randomised controlled trials comparing albumin/PPF with no albumin/PPF, or with a crystalloid solution, in critically ill patients with hypovolaemia, burns or hypoalbuminaemia.
  
  
  METHODS
  We collected data on the participants, albumin solution used, mortality at the end of follow up, and quality of allocation concealment. Analysis was stratified according to patient type.
  
  
  RESULTS
  We found 32 trials meeting the inclusion criteria and reporting death as an outcome. There were 1632 deaths among 8452 trial participants. For hypovolaemia, the relative risk of death following albumin administration was 1.01 (95% confidence interval 0.92-1.10). This estimate was heavily influenced by the results of the SAFE trial, which contributed 91% of the information (based on the weights in the meta-analysis). For burns, the relative risk was 2.40 (1.11-5.19) and for hypoalbuminaemia the relative risk was 1.38 (0.94-2.03). There was no substantial heterogeneity between the trials in the various categories (chi2 = 21.86, df = 25, p = 0.64). The pooled relative risk of death with albumin administration was 1.04 (0.95-1.13).
  
  
  CONCLUSIONS
  For patients with hypovolaemia there is no evidence that albumin reduces mortality when compared with cheaper alternatives such as saline. There is no evidence that albumin reduces mortality in critically ill patients with burns and hypoalbuminaemia. The possibility that there may be highly selected populations of critically ill patients in which albumin may be indicated remains open to question. However, in view of the absence of evidence of a mortality benefit from albumin and the increased cost of albumin compared to alternatives such as saline, it would seem reasonable that albumin should only be used within the context of well concealed and adequately powered randomised controlled trial.
  
  
  CONCLUSIONS
  There is no evidence that giving human albumin to replace lost blood in critically ill or injured people improves survival when compared to giving saline. Trauma, burns or surgery can cause people to lose large amounts of blood. Fluid replacement, giving fluids intravenously (into a vein), is used to help restore blood volume and hopefully reduce the risk of dying. Blood products (including human albumin), non-blood products or combinations can be used. The review of trials found no evidence that albumin reduces the risk of dying. Albumin is very expensive in which case it may be better to use cheaper alternatives such as saline for fluid resuscitation.
authors.affiliation: Dipartimento di Oncologia ed Ematologia, Università degli Studi di Modena e Reggio Emilia, Azienda Ospedaliera Universitaria di Modena, Via del Pozzo 71, 41100, Modena. liberati.alessandro@unimore.it
authors.forename: Alessandro
authors.initials: A
authors.lastname: Liberati
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Moja
authors.forename: Ivan
authors.initials: I
authors.lastname: Moschetti
authors.forename: Gian Franco
authors.initials: GF
authors.lastname: Gensini
authors.forename: Roberto
authors.initials: R
authors.lastname: Gusinu
mesh_terms: D000418:Albumins / Q000627:therapeutic use*; D001798:Blood Proteins / Q000627:therapeutic use*; D016638:Critical Illness / Q000401:mortality* / Q000628:therapy*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012151:Resuscitation / Q000379:methods*; D012709:Serum Albumin; D000075462:Serum Albumin, Human; D012712:Serum Globulins; D012996:Solutions
chemical_list: D000418:Albumins; D001798:Blood Proteins; D012709:Serum Albumin; D012712:Serum Globulins; D012996:Solutions; C008930:plasma protein fraction; D000075462:Serum Albumin, Human